https://www.yiliao.com/index.php?action=history&feed=atom&title=HER2%E9%98%B4%E6%80%A7%E8%83%83%E7%99%8C
HER2阴性胃癌 - 版本历史
2026-04-18T20:19:59Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=HER2%E9%98%B4%E6%80%A7%E8%83%83%E7%99%8C&diff=313294&oldid=prev
223.160.138.166：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-06T07:14:19Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[HER2阴性胃癌]]([[HER2-negative Gastric Cancer]])</strong>是指人表皮生长因子受体2（[[HER2]]/[[ERBB2]]）表达缺失或未达到阳性标准的胃及胃食管结合部腺癌，约占全球胃癌病例的80%-85%。在2026年的精准医学范式中，[[HER2阴性胃癌]]已由“排除性诊断”演变为由<strong>[[CLDN18.2]]</strong>、<strong>[[FGFR2b]]</strong>、<strong>[[PD-L1]]</strong>（[[CPS]]评分）及<strong>[[MSI/dMMR]]</strong>状态驱动的分子分型体系。治疗重心已从单纯化疗跨越至免疫检查点抑制剂（如[[纳武利尤单抗]]）、靶向单抗（如[[佐博妥珠单抗]]）及双特异性抗体（如[[卡度尼利单抗]]）的联合应用，显著改善了晚期患者的生存预后。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">HER2阴性胃癌</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">HER2-negative Gastric Cancer·点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Gastric Cancer Molecular Biomarkers (non-HER2)</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶点：[[CLDN18.2]]•[[PDCD1]]•[[FGFR2]]</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[ICD-10]]</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">C16.9</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">HER2标准</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">IHC 0/1+或FISH(-)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子分型</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[EBV]]•[[MSI]]•[[GS]]•[[CIN]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">主要占比</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约80%以上</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">检测方法</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[IHC]]•[[NGS]]•[[FISH]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026状态</th><br />
<td style="padding: 12px; color: #1e40af;">生物标志物驱动治疗</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">发病机制：异质性进化与多靶点驱动</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[HER2阴性胃癌]]是一个极度异质性的疾病群体。2026年的分子生物学研究将其核心驱动机制归纳为：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>CLDN18.2 通路：</strong><br />
<strong>[[Claudin 18.2]]</strong>（紧密连接蛋白）在胃癌中发生异位表达。作为一种高度特异性的肿瘤相关抗原，它成为HER2阴性胃癌最重要的治疗靶点之一。</li><br />
<li style="margin-bottom: 12px;"><strong>免疫微环境重塑：</strong><br />
通过<strong>[[PD-L1]]</strong>与[[PD-1]]的结合，肿瘤逃避T细胞的免疫监视。2026年共识强调，[[CPS]]评分（综合阳性评分）是预测免疫检查点抑制剂（[[ICI]]）获益的关键指标。</li><br />
<li style="margin-bottom: 12px;"><strong>FGFR 信号通路异常：</strong><br />
约5%-10%的患者存在<strong>[[FGFR2b]]</strong>过表达。这一通路通过激活[[MAPK]]及[[AKT]]信号梯队，驱动肿瘤细胞的增殖与侵袭，常预示较差的化疗应答。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026一线治疗决策矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">分子特征</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">2026核心推荐方案</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">关键证据(研究代号)</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">PD-L1 CPS ≥ 5</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[纳武利尤单抗]] 或 [[替雷利珠单抗]] + 化疗。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[CheckMate-649]]：显著延长[[OS]]。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">CLDN18.2 阳性</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>[[佐博妥珠单抗]]</strong> + [[mFOLFOX6]]。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[SPOTLIGHT]]/[[GLOW]]：确立一线靶向地位。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">FGFR2b 高表达</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>[[贝马妥珠单抗]]</strong> + 化疗。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[FORTITUDE-101]]：针对特定人群的精准获益。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">MSI-H / dMMR</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>[[卡度尼利单抗]]</strong> 或 [[帕博利珠单抗]]。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[KEYNOTE-177]]延伸：免疫治疗作为绝对首选。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026治疗策略：全周期精准干预</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[HER2阴性胃癌]]的管理在2026年已演化为覆盖新辅助、一线及后线的全方位体系：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>围手术期强化：</strong> 2026指南明确建议对于局部晚期患者，采用<strong>[[FLOT方案]]</strong>或化疗联合免疫治疗（[[PerioperativeIO]]），旨在通过术前诱导实现更高比例的病理完全缓解([[pCR]])。</li><br />
<li style="margin-bottom: 12px;"><strong>液体活检监控：</strong> 临床常规应用<strong>[[ctDNA]]</strong>动态监测。通过评估微小残留病灶([[MRD]])状态，精准决定术后辅助化免联合的持续时长及后线二线方案（如[[雷莫西尤单抗]]+[[紫杉醇]]）的启动。</li><br />
<li style="margin-bottom: 12px;"><strong>去化疗模式探索：</strong> 2026年前沿研究正针对MSI-H及高CPS评分人群，探索[[PD-1]]联合[[CTLA-4]]双抗（如[[卡度尼利单抗]]）的“去化疗”一线维持策略。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[CLDN18.2]]：</strong> 2026年HER2阴性胃癌最重要的靶向“新星”。</li><br />
<li style="margin-bottom: 8px;"><strong>[[CPS评分]]：</strong> 决定胃癌免疫治疗能否获益的核心生物标志物标准。</li><br />
<li style="margin-bottom: 8px;"><strong>[[FLOT方案]]：</strong> 目前局部晚期胃癌围手术期化疗的金标准。</li><br />
<li style="margin-bottom: 8px;"><strong>[[卡度尼利单抗]]：</strong> 展现出优于单免疫联合化疗潜力的双特异性抗体。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Janjigian YY, et al. (2021/2026Update).</strong> <em>First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649).</em> <strong>[[The Lancet]]</strong>.<br><br />
<span style="color: #475569;">[权威点评]：CheckMate 649研究确立了免疫联合化疗在HER2阴性、CPS≥5人群中的绝对一线地位。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Shitara K, et al. (2023/2025Revision).</strong> <em>Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT).</em> <strong>[[The Lancet]]</strong>.<br><br />
<span style="color: #475569;">[学术点评]：2026年长效随访证实，针对CLDN18.2高表达人群，[[佐博妥珠单抗]]联合方案已成为新的国际标准。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
HER2阴性胃癌 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关键靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[CLDN18.2]]•[[PD-L1]]•[[FGFR2b]]•[[VEGFR2]]•[[MSI]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">核心药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[纳武利尤单抗]]•[[佐博妥珠单抗]]•[[雷莫西尤单抗]]•[[奥沙利铂]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">诊断指标</td><br />
<td style="padding: 10px 15px; color: #334155;">[[CPS评分]]•[[MSI-H]]•[[CLDN18.2 IHC]]•[[TMB]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">治疗线次</td><br />
<td style="padding: 10px 15px; color: #334155;">[[一线IO+化疗]]•[[二线雷莫西尤联合]]•[[三线TAS-102]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.166